Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
From Retrofit to AI: Akkodis Strengthens Digital Innovation Through Industrial Aerospace Applications at ILA Berlin 202610.6.2026 06:45:00 CEST | Press release
At ILA Berlin 2026, Akkodis will showcase concrete applications in digital engineering, AI-driven analytics and industrial execution across the entire aerospace lifecycle - from initial digital design to real-world aerospace applications. BERLIN, DE / ACCESS Newswire / June 10, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, demonstrates how digital development, artificial intelligence and industrial execution come together to bring new solutions into aerospace applications faster at ILA Berlin 2026. Image: Akkodis at ILA Berlin 2026. Source: AkkodisIn 2026, the aerospace and defense sector is being shaped by strong growth and sustained long-term demand, supported by continued investment in innovation and next-generation technologies. At the same time, increasing pressures on efficiency, availability and sustainability are driving a shift toward solutions that can be rapidly integrated and scaled. At the center of Akkodis' presence is a n
Northfield Announces Change of Corporate Name to Juno International Corporation9.6.2026 21:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 9, 2026 / Northfield Capital Corporation (TSXV:NFD.A) (the "Corporation") today announced that it will change its corporate name to "Juno International Corporation" effective Thursday, June 11, 2026 (the "Name Change"). The trading symbol for the Corporation's class A restricted voting shares (the "Shares") will change to "JUN.A" following the completion of the Name Change. Trading of the Shares on the TSX Venture Exchange under the new name will commence at the open of markets on Thursday, June 11, 2026. There is no change in the capitalization of the Corporation in connection with the Name Change. No action is required by existing shareholders of the Corporation with respect to the Name Change. Outstanding certificates and Direct Registration Statement Advices with respect to the Shares do not need to be exchanged. Upon completion of the Name Change, the Company's new CUSIP number for the Shares will be 482045101 and its new ISIN number will be CA
WLF Energy and Farasis Energy Sign Strategic Partnership Agreement to Accelerate Next-Generation Energy Storage Solutions Globally9.6.2026 15:20:00 CEST | Press release
Partnership combines Farasis Energy's advanced battery technology leadership with WLF Energy's integrated energy platform, AI-driven optimization capabilities, and global deployment strategy STUTTGART, GERMANY / ACCESS Newswire / June 9, 2026 / WLF Energy and Farasis Energy today announced the signing of a Strategic Partnership Agreement to jointly develop, industrialize, and commercialize next-generation battery technologies and energy storage products for global markets. The partnership establishes a long-term framework for collaboration across battery cell technology, battery systems, energy management software, artificial intelligence, and large-scale deployment of energy storage solutions. Together, both companies aim to accelerate the transition toward more affordable, resilient, and sustainable energy infrastructure worldwide. The agreement combines Farasis Energy's extensive experience in advanced battery technology development and manufacturing with WLF Energy's integrated tec
WLF Energy Launches as Europe's Fast, Clean, Bold New Vertically Integrated Clean Energy Champion; Built to Power a Continent9.6.2026 13:30:00 CEST | Press release
Energy platform goes public at The Battery Show Stuttgart, targeting sub-10ct/kWh clean energy for everyone in Europe - and laying the foundation for the continent's energy independence in the decade ahead. STUTTGART, DE / ACCESS Newswire / June 9, 2026 / WLF Energy GmbH today made its public debut at The Battery Show Europe in Stuttgart, unveiling its fully integrated clean-energy platform and long-term mission to deliver affordable, intelligent and sovereign energy infrastructure at global scale. The announcement was delivered by CEO and Chairman Sebastian Wolf, marking the company's first public appearance before a global audience of battery industry leaders, technology innovators and energy investors. The debut signals the arrival of a new kind of European energy company - one designed to integrate generation, storage, intelligence and energy trading into a single platform capable of making clean power the most affordable form of energy in Europe. Founded in 2026, WLF Energy is dev
U.S. Polo Assn. Returns to Downtown London as Official Apparel and Jersey Partner of Chestertons Polo in the Park9.6.2026 13:00:00 CEST | Press release
Over 30,000 Attendees Celebrate the Sport of Polo and ‘An Icon Born from the Game' WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / June 9, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned for the third consecutive year as the Official Apparel and Jersey Partner of Chestertons Polo in the Park, bringing together world-class competition, sport-inspired fashion, thrilling entertainment, and memorable lifestyle experiences for one of London's most anticipated summer sporting events. Held June 5-7, 2026, at Hurlingham Park in central London, the three-day festival welcomed more than 30,000 attendees for a celebration of the sport of polo in one of the world's most iconic urban settings. The Red Sea Global Team Riyadh and the Disney+ Team Rivals fighting for the ball at Chestertons Polo in the Park As the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all teams throughout the tournament with custom-designed perfor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom